Porous materials find widespread application in storage, separation, and catalytic technologies. We report a crystalline porous solid with adaptable porosity, in which a simple dipeptide linker is arranged in a regular array by coordination to metal centers. Experiments reinforced by molecular dynamics simulations showed that low-energy torsions and displacements of the peptides enabled the available pore volume to evolve smoothly from zero as the guest loading increased. The observed cooperative feedback in sorption isotherms resembled the response of proteins undergoing conformational selection, suggesting an energy landscape similar to that required for protein folding. The flexible peptide linker was shown to play the pivotal role in changing the pore conformation

Metal-organic frameworks (MOFs) are crystalline synthetic porous materials formed by binding organic linkers to metal nodes: they can be either rigid 1,2 or flexible. 3 Zeolites and rigid MOFs have widespread applications in sorption, separation and catalysis that arise from their ability to control the arrangement and chemistry of guests in their pores via the shape and functionality of the internal surface defined by their chemistry and structure. 4,5 Their structures correspond to an energy landscape with a single, albeit highly functional, energy minimum. In contrast, proteins function by navigating between multiple metastable structures using bond rotations of the polypeptide, 6,7 where each structure lies in one of the minima of a conformational energy landscape and can be selected according to the chemistry of the molecules interacting with the protein. These structural changes are realised through the mechanisms of conformational selection (where a higher energy minimum characteristic of the protein is stabilised by small molecule binding), and induced fit (where a small molecule imposes a structure on the protein that is not a minimum in the absence of that molecule). 8 Here we show that rotation about covalent bonds in a peptide linker can change a flexible MOF to afford nine distinct crystal structures, revealing a conformational energy landscape characterised by multiple structural minima. The uptake of small molecule guests by the MOF can be chemically triggered by inducing peptide conformational change. This change transforms the material from a minimum on the landscape that is inactive for guest sorption to an active one. Chemical control of the conformation of a flexible organic linker offers a route to modify the pore geometry and internal surface chemistry and thus the function of open-framework materials. Flexible MOF structures 9,10 can be rearranged in the presence of guests through mechanical mechanisms such as the repositioning of a rigid linker about an inorganic unit 11-13 or the relative displacement of two rigid networks, 14 opening a range of routes to control function 15 that are not accessible to rigid frameworks with their single structural minimum (Figure 1). Similar phenomena have been observed in the host-guest chemistry of interlocked cage molecules. 16-18 Alternatively, rotations about bonds involving sp 3 carbons 19-25 allow MOF to access different structures. For example, low energy conformational changes of dipeptide Gly-X linkers produce open and closed forms of Zn(Gly-X)2 frameworks. 26,27 The greater chemical diversity and more complex conformational space of higher order oligopeptides offer MOF with multiple open structures (Figure 1). This could allow interaction with molecules in the pores to select a specific structure for a defined function from the resulting energy landscape. That structure would be accessed through the single bond rotation pathway used by proteins (Figure 1). The tripeptide glycine-glycine-L-histidine (GGH) affords a three-dimensional chiral MOF Zn...

Biological molecules interact with substrates with exquisite precision and (stereo)chemical selectivity, because of their ability to generate suitable receptor sites for substrate molecules. These sites have sufficient diversity in their bonding capabilities to allow subtle differentiation between molecular geometries. There is, thus, considerable interest in the preparation of synthetic materials with aspects of this function.[1] One approach is to use biologically derived components in the assembly of such materials. Amino acid residues are the origin for the functional properties and highly selective substrate-binding ability of many extended biological structures, and so are an attractive option as chiral building blocks for the preparation of bio-analogous materials. Herein, we report a family of synthetic crystalline nanoporous materials in which the internal surface is provided by the amino acid aspartic acid. These materials display enantioselective sorption that is strongly dependent on the spatial distribution of functional groups within the guest molecule.Aspartic acid (NH 2 CH(COOH)CH 2 COOH, aspH 2 ) is an acidic amino acid with one amine and two carboxylic acid groups. As each of these functional groups is capable of binding to metal centers, the aspartate anion has a variety of coordination modes.[2] This polyfunctionality makes it a suitable organic node for the construction of porous metalorganic open-framework materials. [3][4][5][6] Extended frameworks based on metal aspartates have recently been reported; [2] however, the structural motifs in these frameworks are too dense to generate guest-accessible volume. The lactate [7] and tartrate [8] anions have also been used in the construction of metal-organic frameworks.We have sought to generate porosity by connecting metalaspartate units with suitable bidentate linker molecules. This objective requires a synthetic route that avoids the presence

There is an urgent need for new antimalarial drugs with novel mechanisms of action to deliver effective control and eradication programs. Parasite resistance to all existing antimalarial classes, including the artemisinins, has been reported during their clinical use. A failure to generate new antimalarials with novel mechanisms of action that circumvent the current resistance challenges will contribute to a resurgence in the disease which would represent a global health emergency. Here we present a unique generation of quinolone lead antimalarials with a dual mechanism of action against two respiratory enzymes, NADH:ubiquinone oxidoreductase (Plasmodium falciparum NDH2) and cytochrome bc 1 . Inhibitor specificity for the two enzymes can be controlled subtly by manipulation of the privileged quinolone core at the 2 or 3 position. Inhibitors display potent (nanomolar) activity against both parasite enzymes and against multidrug-resistant P. falciparum parasites as evidenced by rapid and selective depolarization of the parasite mitochondrial membrane potential, leading to a disruption of pyrimidine metabolism and parasite death. Several analogs also display activity against liver-stage parasites (Plasmodium cynomolgi) as well as transmission-blocking properties. Lead optimized molecules also display potent oral antimalarial activity in the Plasmodium berghei mouse malaria model associated with favorable pharmacokinetic features that are aligned with a single-dose treatment. The ease and low cost of synthesis of these inhibitors fulfill the target product profile for the generation of a potent, safe, and inexpensive drug with the potential for eventual clinical deployment in the control and eradication of falciparum malaria.T he discovery of atovaquone 20 years ago validated the malaria parasite's mitochondrial electron transport chain (ETC) as an exploitable drug target. Atovaquone targets the ETC at the level of the bc 1 complex (1), with inhibition preventing proton pumping, resulting in a loss of mitochondrial membrane potential (2) and eventual organelle dysfunction, an important function of which is to provide intermediates for pyrimidine synthesis (3, 4). The bc 1 complex requires reducing equivalents provided by ubiquinol, which in turn is generated by membrane-bound dehydrogenases upstream in the ETC that catalyze redox reactions by reducing ubiquinone. The parasite lacks the canonical protonmotive NADH dehydrogenase (Complex I) but instead harbors a bacterial-like type II NADH:ubiquinone oxidoreductase, Plasmodium falciparum NDH2 (PfNDH2) (5). Based on these key observations, we undertook a drug-discovery initiative to develop costeffective inhibitors capable of inhibiting PfNDH2 with the goal of providing antimalarials that overcome the limitations of the expensive atovaquone. Although our initial drug-discovery efforts were focused on optimization of activity versus PfNDH2, we found, during hit-to-lead development, that optimized structures with single-digit nanomolar activity versus the primary target ...

No abstract